JNJ bows out of heart device sector with Cordis sale to Cardinal
This article was originally published in Clinica
Executive Summary
Johnson & Johnson, the one-time leader in the heart stent sector, has decided to leave this device space for good, selling its Cordis business to Cardinal Health for nearly $2bn.